Aims to build on findings from SFXN3 and other potential candidates from the proteomic screen to develop potential therapies for patients suffering with Parkinson's Disease.
- 2017-Present, PhD in Precision Medicine, University of Edinburgh
- 2016-2017, MRes in Health Sciences, University of Bristol
- 2012-2016, Biomedical Sciences (Neuroscience) BSc (Hons), University of Edinburgh
Synapses are a primary pathological target across several neurodegenerative diseases, including Parkinson’s Disease, Alzheimer’s disease and motor neuron disease. The mitochondrial protein Sideroflexin 3 (SFXN3) was recently identified as a potential modulator of synaptic stability.
My project aims to identify molecular interactors of SFXN3 and better understand its role in neurodegeneration in the hopes of developing SFXN3 as a therapeutic target against neurodegenerative diseases.
Huang, Y.T., van der Hoorn, D., Ledahawsky, L.M., Motyl, A.A., Jordan, C.Y., Gillingwater, T.H. and Groen, E.J., 2019. Robust comparison of protein levels across tissues and throughout development using standardized quantitative western blotting. JoVE (Journal of Visualized Experiments), (146), p.e59438.